AI Titans Demand DNA Registry to Thwart Synthetic Bioweapon Threats

In an unprecedented move, the CEOs of OpenAI and Anthropic, together with leading AI researchers, have sent an open letter to U.S. lawmakers, urging tighter oversight of synthetic DNA sequences that could be weaponised. The missive, signed by Sam Altman and Dario Amodei, frames the technology as a double‑edged sword and calls for a national registry of DNA synthesis orders, emphasizing that the accelerating capabilities of generative models mean the time between concept and physical synthesis is shrinking dramatically. The appeal highlights a glaring vulnerability: while the biotech industry already screens orders against known pathogen lists, AI tools can now generate novel, highly transmissible gene sequences without such checks. The signatories propose mandatory real‑time reporting, a vetted whitelist of DNA segments, and stricter licensing for commercial synthesizers, aiming to close the gap between computational design and physical production. A national registry would require each synthesis order to be logged, cross‑referenced against a curated list of high‑risk sequences, and reported to an independent oversight body for periodic audit. This plea arrives amid a resurgence of concern over synthetic biology, recalling the 2020 “Gene Editing Summit” and the 2022 U.S. “Synthetic DNA” pilot that revealed lax oversight. Moreover, the same large‑language models that power ChatGPT can, in theory, draft functional genome scripts, making the line between software and bio‑threat increasingly porous. If adopted, the legislation could reshape the biotech supply chain, spur a new market for compliance technology, and set a precedent for AI‑driven regulatory frameworks. Yet it also risks stifling innovation if overly burdensome, underscoring the need for balanced policy that safeguards security without hampering the rapid evolution of AI‑enabled life sciences.